266 related articles for article (PubMed ID: 7908218)
61. Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer.
El-Mokadem I; Kidd T; Pratt N; Fleming S; Nabi G
Oncotarget; 2016 Nov; 7(45):73045-73054. PubMed ID: 27682877
[TBL] [Abstract][Full Text] [Related]
62. [Frequency of loss of heterozygosity on chromosome 17 in intrahepatic cholangiocarcinoma].
Kim HJ; Kang CD; Lee SJ; Cho SJ; Kim JS
Korean J Gastroenterol; 2006 Sep; 48(3):188-94. PubMed ID: 17047434
[TBL] [Abstract][Full Text] [Related]
63. Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors.
Callahan R; Cropp C; Sheng ZM; Merlo G; Steeg P; Liscia D; Lidereau R
J Cell Biochem Suppl; 1993; 17G():167-72. PubMed ID: 8007695
[TBL] [Abstract][Full Text] [Related]
64. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
65. Clinical Implications of Rabphillin-3A-Like Gene Alterations in Breast Cancer.
Putcha BD; Jia X; Katkoori VR; Salih C; Shanmugam C; Jadhav T; Bovell LC; Behring MP; Callens T; Messiaen L; Bae S; Grizzle WE; Singh KP; Manne U
PLoS One; 2015; 10(6):e0129216. PubMed ID: 26070152
[TBL] [Abstract][Full Text] [Related]
66. Can a phenotype for recessive inheritance in breast cancer be defined?
Ellberg C; Jönsson G; Olsson H
Fam Cancer; 2010 Dec; 9(4):525-30. PubMed ID: 20549370
[TBL] [Abstract][Full Text] [Related]
67. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P; Albonico G; di Iasio MG; Ferretti S; Rinaldi R; Cariello A; Pedriali M; Matteuzzi M; Maestri I; Nenci I
Breast Cancer Res Treat; 2001 Mar; 66(2):135-42. PubMed ID: 11437099
[TBL] [Abstract][Full Text] [Related]
68. Microsatellite analysis of breast carcinoma and corresponding local recurrences.
Regitnig P; Moser R; Thalhammer M; Luschin-Ebengreuth G; Ploner F; Papadi H; Tsybrovskyy O; Lax SF
J Pathol; 2002 Oct; 198(2):190-7. PubMed ID: 12237878
[TBL] [Abstract][Full Text] [Related]
69. Frequent co-amplification of two different regions on 17q in aneuploid breast carcinomas.
Latham C; Zhang A; Nalbanti A; Månér S; Zickert P; Blegen H; Zetterberg A
Cancer Genet Cytogenet; 2001 May; 127(1):16-23. PubMed ID: 11408059
[TBL] [Abstract][Full Text] [Related]
70. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
71. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
72. Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.
Nicoll G; Crichton DN; McDowell HE; Kernohan N; Hupp TR; Thompson AM
Br J Cancer; 2001 Dec; 85(12):1878-82. PubMed ID: 11747329
[TBL] [Abstract][Full Text] [Related]
73. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer.
Bièche I; Champème MH; Matifas F; Hacène K; Callahan R; Lidereau R
Lancet; 1992 Jan; 339(8786):139-43. PubMed ID: 1346009
[TBL] [Abstract][Full Text] [Related]
74. Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer.
Tsuchiya E; Tanigami A; Ishikawa Y; Nishida K; Hayashi M; Tokuchi Y; Hashimoto T; Okumura S; Tsuchiya S; Nakagawa K
Jpn J Cancer Res; 2000 Jun; 91(6):589-96. PubMed ID: 10874210
[TBL] [Abstract][Full Text] [Related]
75. Loss of heterozygosity in tumor tissue in hormonal receptor genes is associated with poor prognostic criteria in breast cancer.
Iobagiu C; Lambert C; Raica M; Lima S; Khaddage A; Peoc'h M; Genin C
Cancer Genet; 2015 Apr; 208(4):135-42. PubMed ID: 25979597
[TBL] [Abstract][Full Text] [Related]
76. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
Nagai MA; Marques LA; Torloni H; Brentani MM
Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
[TBL] [Abstract][Full Text] [Related]
77. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
78. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up.
Thompson AM; Crichton DN; Elton RA; Clay MF; Chetty U; Steel CM
Br J Cancer; 1998 Mar; 77(5):797-800. PubMed ID: 9514060
[TBL] [Abstract][Full Text] [Related]
79. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
80. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters.
Odagiri E; Kanada N; Jibiki K; Demura R; Aikawa E; Demura H
Cancer; 1994 Jun; 73(12):2978-84. PubMed ID: 7911069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
